Previous 10 | Next 10 |
home / stock / chsyf / chsyf news
SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. T...
SHENZHEN, CHINA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The Product has a clear mechanism of action, which is conducive to exerting brain cy...
SHENZHEN, CHINA, July 31, 2023 (GLOBE NEWSWIRE) -- Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited (“CMS” or the ...
SHENZHEN, CHINA, June 29, 2023 (GLOBE NEWSWIRE) -- CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global. Nearly 1600 Chinese companies were included in the selection pool, but only 88 companies, including CMS, were finally sel...
2023-06-18 07:05:00 ET Summary San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Cholesgen (Shanghai) formed a three-year collaboration with AstraZeneca to develop ...
SHENZHEN, CHINA, June 12, 2023 (GLOBE NEWSWIRE) -- CMS is pleased to announce the NDA of the first Diazepam Nasal Spray has been approved for marketing in China. The Product can meet current clinical needs for accessible and convenient treatment option of domestic epilepsy patients 6 year...
SHENZHEN, CHINA, May 30, 2023 (GLOBE NEWSWIRE) -- CMS is pleased to announce the NDA of Tildrakizumab Injection under the brand name of ILUMETRI, a monoclonal antibody specifically targeting the p19 subunit of IL-23, has been approved in China. ILUMETRI is indicated for the treatment of adu...
Starting its Industrial Investment in Biotech Companies, China Medical System (0867.HK) has Accelerated its Flywheel of Innovation HONG KONG, Apr 26, 2021 - (ACN Newswire) - China Medical System Holdings Limited (0867.HK) ("CMS" or the "Company") has been active in the market ...
China Medical System (0867.HK): Accelerating Development and Stepping to a New Height Driven by Innovation HONG KONG, Apr 2, 2021 - (ACN Newswire) - As the earning season approaches, once again listed pharmaceutical companies are attracting the attention of the public. Recentl...
China Medical System (00867) Ushers in a Revaluation with its Continuous Growth and Synergy between Innovative Business and New Businesses HONG KONG, Mar 30, 2021 - (ACN Newswire) - Turnover and net profit increased at the same time, innovative pipeline continued to expand, an...
News, Short Squeeze, Breakout and More Instantly...
China Medical Sys Hldgs Company Name:
CHSYF Stock Symbol:
OTCMKTS Market:
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unme...
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, De...
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines ...